Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN21353
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN21353 is an investigational bispecific T-cell engager (TCE) antibody designed to target six-transmembrane epithelial antigen of the prostate 1 (STEAP1) on tumor cells and CD3 on T cells. Developed by Regeneron Pharmaceuticals, REGN21353 is being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). By simultaneously binding to STEAP1 and CD3, the antibody facilitates the formation of a cytolytic synapse, redirecting cytotoxic T-cell activity to selectively lyse STEAP1-expressing prostate cancer cells. It is being studied as a monotherapy and in combination with nezastomig (a PSMAxCD28 co-stimulatory bispecific antibody) and sarilumab.
02
Targets
STEAP1 (Six-transmembrane epithelial antigen of prostate 1)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on REGN21353.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN21353.